source
- Cellectis to cut 70% of staff as it shifts focus from allogeneic CAR-T to in vivo gene editingCellectis announced that roughly seven out of ten employees will be let go as the Paris‑based biotech restructures its operations. The company previously abandoned its two clinical‑stage allogenei…
- FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapsesThe U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…